Abstract 1496P
Background
Determining when to initiate renal replacement therapy (RRT) in cancer patients with acute kidney injury (AKI) can pose a considerable challenge, particularly for those with limited treatment options for cancer and a short life expectancy. This study aims to explore the predictors of short-term mortality among cancer patients undergoing hemodialysis following AKI.
Methods
Between January 2014 and April 2023, this retrospective study included 139 hospitalized patients with various cancers who underwent hemodialysis for AKI in Hacettepe University Oncology Hospital. Clinical and laboratory features, comorbidities, and survival outcomes were collected. Predictors of 30-day mortality after initiation of hemodialysis were evaluated.
Results
Median age was 64 and 39% were females. ECOG performance score was 3-4 in 48%. Median Charlson comorbidity index was 8. Among the patients, 26% had gastrointestinal cancers and 23% had lung cancer. Notably, the etiology of AKI was prerenal-renal in 93% of the cases, with 45% of AKI instances occurring during hospitalization. 111 patients (80%) died within 30 days after the first hemodialysis session. In multivariate analysis, serum albumin less than 2.5 g/dl (OR: 3.14, 95% CI; 1.23-8.04, p=0.017), presence of sepsis (OR: 3.50, 95% CI; 1.34-9.10, p=0.010), prerenal-renal AKI (compared to postrenal AKI) (OR: 6.06, 95% CI 1.38-26.56, p=0.017) were associated with higher 30-day mortality. Patients with none of these risk factors had 33% 30-day mortality while those with all the identified risk factors had significantly higher rate of 93% (p<0.001).
Conclusions
In this study, patients with sepsis, pre-renal or renal AKI, and low albumin levels had higher early mortality rates after hemodialysis. Identifying AKI patients unlikely to benefit from RRT may assist clinicians in making informed decisions.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1481P - A case-control study of drug-eluting microspheres and blank microspheres in bronchial artery embolization for hemoptysis in non-small cell lung cancer
Presenter: Tongguo Si
Session: Poster session 10
1482P - Percutaneous transhepatic biliary drainage (PTBD) for palliation of jaundice in patients of unresectable/disseminated carcinoma gall bladder with hilar block: Is it a worthwhile enterprise?
Presenter: Saurabh Galodha
Session: Poster session 10
1484P - Inflammatory patterns of ascites in patients with solid tumors
Presenter: Julia Berger
Session: Poster session 10
1485P - Mitigating symptom clusters of patients with metastatic cancer through a remote physical exercise program (EXIO)
Presenter: Paulo Bergerot
Session: Poster session 10
1486P - A personalized rehabilitation pilot program for improving QOL of unresectable metastatic lung cancer patients
Presenter: Shani Shilo
Session: Poster session 10
1487P - Telemonitoring system effectiveness for alleviating cancer pain in patients with advanced cancer
Presenter: Shiori Yoshida
Session: Poster session 10
1488P - Use of mobile app “SUPPORT+” to enhance community palliative care in advanced cancer patients: A feasibility study
Presenter: Wendy Chan
Session: Poster session 10
1489P - Factors influencing adherence to electronic patient-reported outcomes in palliative cancer care
Presenter: Sarah Gomes
Session: Poster session 10
1490P - Health-related quality of life of cancer patients on chemotherapy and its relationship with caregiver strain: A cross-sectional analytical study
Presenter: Herald Mapa
Session: Poster session 10
Resources:
Abstract